Raymond James Financial
DYN icon

Raymond James Financial’s Dyne Therapeutics DYN Stock Holding History

Raymond James Financial’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.19M Sell
451,644
-78,694
-15% -$1.36M ﹤0.01% 2183
2025
Q4 		$10.4M Buy
530,338
+453,426
+590% +$8.59M ﹤0.01% 1933
2025
Q3 		$973K Buy
76,912
+25,432
+49% +$290K ﹤0.01% 3689
2025
Q2 		$490K Sell
51,480
-1,613
-3% -$17.8K ﹤0.01% 4018
2025
Q1 		$555K Sell
53,093
-46,235
-47% -$661K ﹤0.01% 3879
2024
Q4 		$2.34M Buy
+99,328
New +$2.94M ﹤0.01% 2851

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Raymond James Financial's DYN Position: Q1 2026 in Review

Raymond James Financial reduced its Dyne Therapeutics (DYN) stake by 15% in Q1 2026, selling an estimated $1.36M and leaving 451,644 shares worth $8.19M. The position accounts for ﹤0.01% of the portfolio, ranked #2183.

Raymond James Financial first reported a position in DYN in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.4M in Q4 2025. 228 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Raymond James Financial held 451,644 shares of Dyne Therapeutics worth $8.19M as of Q1 2026.
  • Raymond James Financial sold 78,694 Dyne Therapeutics shares in Q1 2026, an estimated $1.36M.
  • Dyne Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #2183 holding.
  • Raymond James Financial first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Dyne Therapeutics position peaked at $10.4M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.